Introduction
The ORALEV randomized controlled trial demonstrated that preoperative oral antibiotics (OA) before colon surgery reduces surgical-site infections. However, concerns were raised about the potential risk of antibiotic resistance.
Aims & Methods
This study aimed to assess if OA in the ORALEV trial led to increased long-term infection-related complications due to antibiotic resistance.
This is a retrospective analysis of 3-year follow-up data from 529 patients in the ORALEV trial. Primary outcome: risk of infectious complications and antibiotic resistance in patients with vs without OA. Secondary: long-term complications, effect on COVID-19 risk.
Results
| [ALL]
| Experimental
| Control
| p |
| N=529
| N=264
| N=265 |
|
Hospital admission due to infection
| 14 (2.65%)
| 7 (2.65%) | 7 (2.64%) | 1.000
|
Need for antibiotic treatment
| 8 (1.51%)
| 3 (1.14%) | 5 (1.89%) | 0.715
|
COVID-19
| 5 (0.95%)
| 4 (1.52%) | 1 (0.38%) | 0.218
|
Long-term complication
| 16 (3.02%) | 4 (1.52%) | 12 (4.53%) | 0.077
|
Long-term unplanned surgery
| 11 (2.08%) | 1 (0.38%) | 10 (3.77%) | 0.015
|
| Any type of hospital readmission | 62 (11.7%) | 33 (12.5%) | 29 (10.9%) | 0.674
|
| 3-year mortality | 47 (8.88%) | 24 (9.09%) | 23 (8.68%) | 0.989
|
| Overall Survival (3-year) | 90.6 (95%CI 88.1; 93.2) | 90.4 (95%CI 86.8; 94.1) | 90.9 (95%CI 87.4; 94.5) | 0.819 |
536 patients from the ORALEV trial were assessed for eligibility, of whom 529 were included (265 no OA vs 264 OA). The incidence of infective complications resulting in hospital admissions (n=7, 2.6% vs n=7, 2.6%, no OA vs OA), antibiotic treatment (n=5, 1.9% vs n=3, 1.1%. p=0.715), and COVID-19 (n=1, 0.4% vs n=4, 1.5% p=0.22) did not differ. Two patients in each group required treatment with carbapenems. No differences were observed between the groups regarding readmissions for any complication (n=29, 10.9% vs n=33, 12.5%, p=0.67). After removing COVID-19 admissions, COPD was associated with need for antibiotic treatment in the long-term (HR 5.13, 95%CI 1.28-20.54) irrespective of OA administration. The rates of postoperative hernia (n=11, 4.1% vs n=4, 1.5% p=0.11) and indication for hernia repair (9/11, 81.8% vs 1/4, 25%, p=0.08) were higher in non-OA group, but not statistically different.
Conclusion
OA do not increase the risk of long-term infective complications and need for advanced antimicrobial treatment. COPD increased the risk of subsequent need for antibiotic treatment. Hernia rates and need for surgical repair might be higher in those patients who did not receive OA.
References
Espin Basany E, Solís-Peña A, Pellino G, Kreisler E, Fraccalvieri D, Muinelo-Lorenzo M, et al. Preoperative oral antibiotics and surgical-site infections in colon surgery (ORALEV): a multicentre, single-blind, pragmatic, randomised controlled trial. lancet Gastroenterol Hepatol. 2020 Aug;5(8):729–38.